Related references
Note: Only part of the references are listed.Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients
Denis Maillet et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer
Ryon P. Graf et al.
EUROPEAN UROLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells
Manuel Abreu et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients
Ann-Kathrin Bittner et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer
Ingeborg E. de Kruijff et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice
Andreas Schneeweiss et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2019)
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer
Channing J. Paller et al.
PROSTATE (2019)
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Ivana Bratic Hench et al.
CANCERS (2019)
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
Carlo Cattrini et al.
CANCERS (2019)
Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
Claudia Hille et al.
CELLS (2019)
Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients
Natalia Krawczyk et al.
BMC CANCER (2019)
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
Eline A. M. Ruigrok et al.
PHARMACEUTICS (2019)
Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility
Klaus Pantel et al.
CLINICAL CHEMISTRY (2019)
Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer
Agnieszka Morgenroth et al.
BREAST CANCER RESEARCH (2019)
PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer
Ann-Christin Baranski et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Androgen blockade based clinical trials landscape in triple negative breast cancer
Yaqin Shi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Giuseppe Bronte et al.
BMC CANCER (2018)
In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells
Amin El-Heliebi et al.
CLINICAL CHEMISTRY (2018)
Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
Priyanka Sharma
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
Giuseppe Bronte et al.
TRANSLATIONAL ONCOLOGY (2018)
Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer
Monika Pizon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
A conduit to metastasis: circulating tumor cell biology
Douglas S. Micalizzi et al.
GENES & DEVELOPMENT (2017)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2017)
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer A Review
Miho Kono et al.
JAMA ONCOLOGY (2017)
Androgen receptor expression on circulating tumor cells in metastatic breast cancer
Takeo Fujii et al.
PLOS ONE (2017)
The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
Aurelio Bartolome Castrellon et al.
ONCOLOGY REVIEWS (2017)
Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases
Mariz Kasoha et al.
CLINICAL & EXPERIMENTAL METASTASIS (2017)
Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer
Maren Bredemeier et al.
CLINICAL CHEMISTRY (2017)
RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients
Corinna Keup et al.
CANCER RESEARCH (2017)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
Bahriye Aktas et al.
BMC CANCER (2016)
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
Mohammad A. Aleskandarany et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
Weimin Li et al.
CLINICAL CANCER RESEARCH (2016)
Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients
Tilman Todenhoefer et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
Maren Bredemeier et al.
ONCOTARGET (2016)
Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer
Wendy Onstenk et al.
ONCOTARGET (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Characterization of different CTC subpopulations in non-small cell lung cancer
Annkathrin Hanssen et al.
SCIENTIFIC REPORTS (2016)
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
Sabine Kasimir-Bauer et al.
BREAST CANCER RESEARCH (2016)
Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy
Shyamala Maheswaran et al.
CANCER RESEARCH (2015)
68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
Francesco Ceci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PSMA PET in Prostate Cancer
Hossein Jadvar
JOURNAL OF NUCLEAR MEDICINE (2015)
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
Martina Weineisen et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
David T. Miyamoto et al.
SCIENCE (2015)
Targeting the Androgen Receptor in Breast Cancer
KeeMing Chia et al.
CURRENT ONCOLOGY REPORTS (2015)
Expression of androgen receptor splice variants in clinical breast cancers
Theresa E. Hickey et al.
ONCOTARGET (2015)
Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
Lee J. McGhan et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis
Francisco E. Vera-Badillo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations
Mirco Pistelli et al.
CANCERS (2014)
Expression of androgen receptors in triple negative breast carcinomas
Ivana Mrklic et al.
ACTA HISTOCHEMICA (2013)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Prostate-specific membrane antigen-based imaging
Joseph R. Osborne et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Decreased Androgen Receptor Expression Is Associated With Distant Metastases in Patients With Androgen Receptor Expressing Triple-Negative Breast Carcinoma
Lisa M. Sutton et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
David T. Miyamoto et al.
CANCER DISCOVERY (2012)
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Rong Hu et al.
CLINICAL CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Share Paper
